预包装纳洛酮用于疑似阿片类药物过量:非法制造芬太尼时代的区域毒物中心数据回顾性研究
该回顾性研究分析了马里兰毒物中心2015年1月1日至2017年10月15日报告的1139例预包装纳洛酮给药案例,主要终点为逆转阿片所致中枢神经和呼吸抑制的平均预包装纳洛酮剂量。结果显示,79.2%的过量者在中位平均剂量3.12 mg后毒性逆转;2015至2017年间平均剂量从2.12 mg增至3.63 mg(P < .0001),而逆转率从82.1%降至76.4%(P = .04)。55例阿片相关死亡中36例(65.5%)检出芬太尼或其类似物。结论认为预包装纳洛酮在多数未分化阿片中毒中可逆转毒性,但剂量增加而逆转率下降的趋势可能为多因素所致,包括非法制造芬太尼及其类似物可获得性增加。
要点
- 1139例预包装纳洛酮给药中,79.2%(886例)在平均剂量3.12 mg后阿片毒性逆转。
- 2015至2017年平均预包装纳洛酮剂量从2.12 mg升至3.63 mg(P < .0001),逆转率从82.1%降至76.4%(P = .04)。
- 执法人员在91.0%(1035例)中给予预包装纳洛酮,主要途径为鼻内(97.9%,1051例)。
- EMS对291例追加纳洛酮(平均2.2 mg),其中94.2%(254例)逆转阿片毒性。
- 55例阿片相关死亡中36例(65.5%)检出芬太尼或其类似物。
适用人群与场景
- 疑似或未分化阿片类药物过量者,数据来自马里兰毒物中心2015年1月1日至2017年10月15日报告的预包装纳洛酮给药案例。
- 平均年龄34.3岁,68.8%(781例)为男性;98.2%(958例)存在呼吸抑制,97%(1097例)无反应。
处置流程与药物剂量
- 执法人员给予预包装纳洛酮,主要途径为鼻内(97.9%,1051例);EMS对291例追加纳洛酮,平均剂量2.2 mg。
研究设计与关键结果
- 回顾性研究,纳入1139例预包装纳洛酮给药;主要终点为逆转阿片所致中枢神经和呼吸抑制的平均预包装纳洛酮剂量。
- 毒性逆转率79.2%(886例),平均预包装纳洛酮剂量3.12 mg。
- 2015至2017年平均预包装纳洛酮剂量从2.12 mg增至3.63 mg(P < .0001),逆转率从82.1%降至76.4%(P = .04)。
- 182例(15.9%)拒绝转运;转运至医院者中73.4%(569例)经治疗离院,12.4%(96例)需住院。
- 生存率96%(1092例);40例在现场宣布死亡。55例阿片相关死亡中36例(65.5%)检出芬太尼或其类似物。
证据类型、等级与局限
- 证据类型:回顾性研究,基于区域毒物中心数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为预包装纳洛酮在多数未分化阿片中毒中可逆转毒性,但2015至2017年间剂量增加而逆转率下降的趋势可能为多因素所致,包括非法制造芬太尼及其类似物可获得性增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Prepacked naloxone kits (PNKs) are frequently used to reverse opioid intoxication. It is unknown if the presence of illicitly manufactured fentanyl and its analogs (IMFs) in heroin supply is affecting the PNK doses given by laypersons. We investigated the trend of PNK dose administered to reverse opioid toxicity in suspected/undifferentiated opioid intoxication.Methods: We retrospectively reviewed PNK administrations reported to the Maryland Poison Center between 1 January 2015 and 15 October 2017. Primary outcome was the mean PNK dose administered to reverse opioid-induced central nervous system and ventilatory depression. Secondary outcomes included the reversal rate of opioid toxicity, patient disposition, and survival rate.Results: Our analysis involved 1139 PNK administrations. The mean age of subjects was 34.3 years; 68.8% (n = 781) were male. Ventilatory depression was present in 98.2% (n = 958) of cases, and 97% (n = 1097) were unresponsive. Law enforcement administered the majority of PNK (91.0%; n = 1035); the primary route was intranasal (97.9%; n = 1051). Toxicity was reversed in 79.2% (n = 886) of overdose victims after a mean PNK dose of 3.12 mg. EMS personnel gave 291 subjects additional naloxone (mean: 2.2 mg), reversing opioid toxicity in 94.2% (n = 254). Between 2015 and 2017, the mean PNK dose increased from 2.12 to 3.63 mg (p < .0001) while the reversal rate decreased from 82.1% to 76.4% (p = .04). One hundred and eighty-two patients (15.9%) refused transport; of those transported to a hospital, 73.4% (n = 569) were treated and released and 12.4% (n = 96) required hospitalization. Ninety-six percent (n = 1092) of the subjects survived. Forty subjects were pronounced dead at the scene. Fentanyl or its analog was detected in 36 of 55 opioid-related deaths (65.5%).Conclusions: PNK administration reversed toxicity in the majority of patients with undifferentiated opioid intoxication. Between 2015 and 2017, increasing doses of PNK were administered but the reversal rate decreased. These trends are likely multifactorial, including increasing availability of IMFs.
参考来源
- Mahonski SG, Leonard JB, Gatz JD, et al. Prepacked naloxone administration for suspected opioid overdose in the era of illicitly manufactured fentanyl: a retrospective study of regional poison center data. Clin Toxicol (Phila). 2019. PMID: 31092050. doi:10.1080/15563650.2019.1615622
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。